8-K: REGEN BIOPHARMA Issues Shares for Debt, Raises Capital

REGEN BIOPHARMA, INC. announced the issuance of over 21 million common shares to satisfy convertible debt and raise $50,000 in cash.

Summary

• Issued 5,000,000 common shares on January 15, 2026, to satisfy $11,449 of principal convertible indebtedness and $8,101 of accrued interest, totaling $19,550.
• Issued 5,302,732 common shares on January 29, 2026, to satisfy $12,000 of principal convertible indebtedness and $1,000 of accrued interest, totaling $13,000.
• Issued 11,111,111 common shares on January 30, 2026, for $50,000 in cash consideration.
• All shares were issued without underwriters or commissions, directly through management, under Section 4(a)(2) of the Securities Act or a Tier 2 Regulation A Offering.
• As of February 2, 2026, the company has 129,468,577 common shares issued and outstanding.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a highly negative development due to significant shareholder dilution at extremely low implied valuations, indicating potential financial distress and challenges in securing more favorable funding.

Positives

• Successfully converted $32,550 of convertible indebtedness (principal and interest) into equity, reducing liabilities.
• Raised $50,000 in cash through a Tier 2 Regulation A Offering.
• Avoided underwriting fees by selling shares directly through management.

Negatives

• Significant dilution of existing shareholders, with over 21 million new shares issued, increasing total outstanding shares to 129,468,577.
• The implied valuation for debt conversion and cash raise is very low, ranging from approximately $0.00245 to $0.0045 per share.
• Reliance on converting debt to equity and small capital raises suggests potential financial strain.

Risks

• Share Dilution: The issuance of 21,413,843 new common shares significantly dilutes the ownership percentage of existing shareholders.
• Low Valuation: The implied share prices for the debt conversions and cash raise are extremely low, indicating a potentially distressed valuation for the company's equity.
• Funding Challenges: The need to convert debt into equity and raise small amounts of capital suggests ongoing challenges in securing more substantial or favorable financing.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that small biopharma companies often face significant capital requirements for research and development, frequently resorting to equity issuances or convertible debt to fund operations. The current transactions, involving debt conversion at very low implied valuations and a modest cash raise, suggest REGEN BIOPHARMA is navigating typical early-stage funding challenges, potentially indicating limited access to more favorable financing options compared to larger, more established industry players.

Comparison to Industry Standards

• The implied share prices of $0.00245 to $0.0045 are significantly below typical valuations for publicly traded biopharma companies, which often trade in dollars or tens of dollars per share, even for early-stage firms.
• The reliance on converting debt at such low valuations is common for highly speculative or financially distressed micro-cap companies, contrasting with more mature biopharma firms like Amgen or Pfizer that typically raise capital through larger, more structured offerings or have strong cash flows.
• The direct sale of shares by management without underwriters is typical for very small capital raises or private placements, but less common for companies seeking broader market access or significant institutional investment, unlike a company such as Moderna which would use major investment banks for large public offerings.

Stakeholder Impact

• Shareholders: Significant dilution of existing shareholders' ownership and value due to the issuance of over 21 million new shares at very low implied prices.
• Creditors (Convertible Debt Holders): Convertible debt holders had their debt satisfied by receiving equity, which could be positive if they believe in the long-term potential of the company, but also indicates the company's inability to repay in cash.

Key Dates

Recommendation

The significant dilution of over 21 million shares at extremely low implied valuations (sub-penny per share) to satisfy a relatively small amount of debt and raise minimal cash is a strong negative signal. This indicates severe financial distress and a highly unfavorable capital structure for existing shareholders. The company's inability to secure more favorable financing terms or avoid such dilutive measures suggests a high risk of further value erosion, making it a strong sell for seasoned investors.

Keywords

REGEN BIOPHARMA, equity issuance, debt conversion, capital raise, dilution, 8-K filing, unregistered sales, Regulation A, biopharma